The cancer cells with normal levels of PARP-1 but decreased enzymatic activity as noted by reduced level of endogenous PARylation are more resistant to PARPi (Oplustilova et al., 2012; Figure 1, step B, arrow #9). The gene discussed is PARP1; the disease is cancer.